Cancer Imaging

Table 1 The baseline characteristics between the two groups before and after PSM analysis

From: Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study

Variables	Before PSM			After PSM
Variables	TACE + Sorafenib (n = 129)	TACE + aptinib (n = 251)	p	TACE + Sorafenib (n = 116)	TACE + aptinib (n = 116)	p
Sex			0.201			0.082
Male	112	205		101	91
Female	17	46		15	25
Age (y)	55.04 ± 12.05	55.38 ± 11.77
Viral hepatitis						0.120
Yes	100	203	0.441	94	84
No	29	48		22	32
Child–Pugh			0.992			0.293
A	76	148		65	57
B	53	103		51	59
AFP			0.785			0.427
≤ 400 ng/ml	81	154		68	62
> 400 ng/ml	48	97		48	54
ECOG PS			0.262			0.351
0	81	172		71	64
1/2	48	79		45	52
Number of nodules			0.222			0.232
≤ 3	64	108		54	45
> 3	65	143		62	71
Tumor size			0.005			0.089
≤ 5 cm	35	105		30	42
> 5 cm	94	146		86	74
Liver cirrhosis			0.081			0.127
Yes	79	176		78	66
No	50	75		48	60
MVI			0.833			0.511
Yes	71	141		60	55
No	58	110		56	61
Extrahepatic metastasis			0.076			0.280
Yes	23	65		31	24
No	106	186		85	92
Number of TACE			0.255			0.419
≤ 3	52	117		48	42
> 3	77	135		68	74

TACE Transcatheter arterial chemoembolization, PSM Propensity score matching, ECOG PS Eastern Cooperative Oncology Group Performance Status, AFP Alpha-fetoprotein, MVI Microvascular invasion

Back to article page

ISSN: 1470-7330

Contact us

Submission enquiries: alyzza.javate@springernature.com
General enquiries: info@biomedcentral.com